Company profile: Schwarz Pharma
1.1 - Company Overview
Company description
- Provider of pharmaceutical product development, bringing approved and late-stage new compounds with complementary therapeutic and geographic focus, supported by strong talent and cultural fit.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Schwarz Pharma
Cullgen
HQ: United States
Website
- Description: Provider of drug discovery services leveraging its uSMITE platform to develop targeted protein degraders using novel E3 ligands for diseases lacking effective therapies, including cancer, inflammation, autoimmune, and neurodegenerative disorders; pipeline includes CG001419, an orally bioavailable pan-TRK degrader in phase I/II clinical trial for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullgen company profile →
Adnexus Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adnexus Therapeutics company profile →
4P Therapeutics
HQ: United States
Website
- Description: Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P Therapeutics company profile →
Palatin Technologies
HQ: United States
Website
- Description: Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palatin Technologies company profile →
CTI Science
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on improving human and animal health, developing a flagship product for submission for regulatory drug approval. Founded in 2007 by Dr. Boyd E. Haley, based in Lexington, Kentucky, United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI Science company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Schwarz Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Schwarz Pharma
2.2 - Growth funds investing in similar companies to Schwarz Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Schwarz Pharma
4.2 - Public trading comparable groups for Schwarz Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →